Project Grant HT9425261E277
Award Date 6/1/26
Completion Date 5/31/30
Dollars Obligated $1.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $735,751 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025, through August 31, 2028. The award supports research and development activities focused on combining TROP2-directed chimeric antigen receptor natural killer (CAR-NK) cells with HIF2A (hypoxia-inducible factor 2-alpha) inhibition as an...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $490,500 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025, through August 31, 2028. The grant funds research combining TROP2-directed chimeric antigen receptor natural killer (CAR-NK) cells with HIF2A (hypoxia-inducible factor 2-alpha) inhibition to develop novel immunotherapy approaches for pancreatic...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $349,996 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period June 15, 2026 through June 14, 2028. The award funds research on metabolic rewiring of chimeric antigen receptor (CAR)-T cells to counter the hostile tumor microenvironment in ovarian cancer. This research aims to develop enhanced immunotherapy approaches by...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $1,431,215 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded October 1, 2025, with a completion date of September 30, 2028. The award funds research focused on building T-cell products for neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNST) through antigen discovery and...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $817,496 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. The award funds research to investigate the PRMT3-IGF2BP1 axis-mediated epitranscriptomic reprogramming as a novel therapeutic strategy to overcome immunotherapy resistance in clear cell renal cell carcinoma...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $1.35 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the three-year period from October 1, 2025, through September 30, 2028. The award funds research focused on building T-cell products for neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNST) through antigen discovery and...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $893,525 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. The award supports research targeting neuronal mimicry in SMARCB1-deficient renal medullary carcinoma treatment. This three-year initiative will deliver translational and clinical research services focused on developing...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $489,767 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective October 1, 2025, through September 30, 2028. The award supports research titled "Building T-Cell Products in NF1-Associated MPNST Through Antigen Discovery and Epigenome Targeting," which addresses the development of therapeutic T-cell immunotherapy...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $414,472 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025 through August 31, 2028. The award funds research targeting neuronal mimicry mechanisms in SMARCB1-deficient renal medullary carcinoma treatment. This research represents a translational oncology initiative designed to advance therapeutic...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $5.47M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025, through August 31, 2029. The award funds research aimed at targeting ganglioside GD2 to overcome chemotherapy resistance in triple-negative breast cancer. This research initiative represents translational and clinical investigation...